News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Presentation from the AGM is now available on the company’s website

April 14, 2016

PledPharma AB
Company Announcement

Presentation from the AGM is now available on the company's website

Stockholm, 2016-04-14 16:00 CEST (GLOBE NEWSWIRE) -- 
Today at PledPharma’s Annual General Meeting the company's CEO, Jacques
Näsström, presents milestones achieved during the past year. The focus of the
presentation is on the company's most advanced project PledOx®. Among others,
Näsström mentions that active discussions are being held with a number of
potential partners in the ongoing process of finding one or more appropriate
commercial partners for continued development. 

The full presentation from the AGM is available on the company website.

For more information please contact:

Jacques Näsström, CEO, phone: +46 737 130 979

About PledPharma

PledPharma develop new drugs that protect the body against oxidative stress - a
potentially disabling and sometimes life-threatening condition that can be
caused by chemotherapy and acetaminophen poisoning. The company's most advanced
project PledOx® reduces nerve damage associated with chemotherapy. Positive
results from phase IIb study PLIANT were presented in the spring of 2015. The
drug candidate Aladote® is developed to reduce the risk of acute liver failure
associated with acetaminophen poisoning. The project PP-099 aims to limit the
damage that occurs to the heart muscle during a heart attack. PledPharma
(STO:PLED) is listed on NASDAQ OMX First North. Erik Penser Bankaktiebolag is
the Certified Adviser. For further information, please visit



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10